compound 071

Compound 071 is an experimental chalcone-based small molecule inhibitor identified through 3D-QSAR (Quantitative Structure-Activity Relationship) modeling for the treatment of ovarian cancer. Validated experimentally against the A2780 ovarian cancer cell line, the compound demonstrates potent antiproliferative activity. Its primary mechanism of action involves the induction of intracellular reactive oxygen species (ROS), which leads to oxidative stress and triggers programmed cell death (apoptosis). This compound is specifically designed to address the challenge of chemoresistance in late-stage gynecological malignancies, representing a lead candidate in the development of targeted chalcone derivatives for oncology.